Cantor Fitzgerald Raises BioMarin Pharmaceutical's 2026 EPS Forecast

Summary

Cantor Fitzgerald analysts have raised their FY2026 earnings per share estimate for BioMarin Pharmaceutical (NASDAQ:BMRN) from $4.29 to $4.84. The current consensus estimate for the company’s full-year earnings is $3.15 per share. Various analysts have set price targets for BMRN, with Wolfe Research at $95.00 and Goldman Sachs at $104.00. The stock opened at $59.96, with a market cap of $11.50 billion and a PE ratio of 17.77. Institutional investors hold 98.71% of the stock, and insider activity includes a recent sale by CAO Erin Burkhart.Market Beat

Impact Analysis

The event is classified as a company-level event as it pertains specifically to BioMarin Pharmaceutical. The raised earnings estimates by Cantor Fitzgerald suggest a positive outlook on the company’s future financial performance, which is likely to influence investor sentiment positively. The revised estimate is significantly higher than the current consensus of $3.15 per share, indicating potential undervaluation or improved business prospects. First-order effects include potential stock price appreciation as investors adjust their valuations based on the new earnings projections. The price targets set by Wolfe Research and Goldman Sachs also suggest room for stock price growth, potentially attracting more investors. Second-order effects could involve increased analyst coverage and interest from institutional investors, given the high percentage of institutional holdings. Investment opportunities may exist in taking positions in BioMarin stocks, considering the potential upside reflected in the revised earnings and price targets.Market Beat